These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1660 related articles for article (PubMed ID: 31090928)

  • 21. Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
    Mushtaq A; Iftikhar A; Hassan H; Lakhani M; Sagar F; Kamal A; Zahid U; Ali Z; Razzaq F; Zar MA; Hassan SF; Safdar A; Raychaudhuri S; Anwer F
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):447-461. PubMed ID: 31060991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
    Pierceall WE; Amatangelo MD; Bahlis NJ; Siegel DS; Rahman A; Van Oekelen O; Neri P; Young M; Chung W; Serbina N; Parekh S; Agarwal A; Thakurta A
    Clin Cancer Res; 2020 Nov; 26(22):5895-5902. PubMed ID: 32928795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
    Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
    Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
    Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
    Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
    Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
    Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
    Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Kampfenkel T; Liu W; Wang J; Kosh M; Tran N; Carson R; Sonneveld P
    Lancet Haematol; 2023 Oct; 10(10):e813-e824. PubMed ID: 37793772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daratumumab plus lenalidomide and dexamethasone
    Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
    Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
    LeBlanc R; Mian H; Reece D; Masih-Khan E; Kardjadj M; Jimenez-Zepeda VH; McCurdy A; Song K; Sebag M; Louzada M; White D; Stakiw J; Kotb R; Reiman A; Aslam M; Gul E; Venner CP
    Br J Haematol; 2022 Jul; 198(1):93-102. PubMed ID: 35383886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
    He J; Berringer H; Heeg B; Ruan H; Kampfenkel T; Dwarakanathan HR; Johnston S; Mendes J; Lam A; Bathija S; Mackay EK
    Adv Ther; 2022 Sep; 39(9):4230-4249. PubMed ID: 35876974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
    Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
    Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daratumumab plus bortezomib and dexamethasone
    Spencer A; Lentzsch S; Weisel K; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka AK; Quach H; Lee C; Barreto W; Corradini P; Min CK; Scott EC; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Soong D; Casneuf T; Chiu C; Amin H; Qi M; Thiyagarajah P; Sasser AK; Schecter JM; Mateos MV
    Haematologica; 2018 Dec; 103(12):2079-2087. PubMed ID: 30237264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
    Dima D; Mansour R; Davis JA; Minchak M; Goel U; Atallah R; Logan E; Tabak C; Rashid A; Ahmed N; Abdallah AO; Hashmi H
    Eur J Haematol; 2024 Jun; 112(6):975-983. PubMed ID: 38382632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
    Matsue K; Sunami K; Matsumoto M; Kuroda J; Sugiura I; Iwasaki H; Chung W; Kuwayama S; Nishio M; Lee K; Iida S
    Int J Hematol; 2022 Jul; 116(1):122-130. PubMed ID: 35429329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma.
    Mohyuddin GR; Hampton J; Aziz M; Khuder S; Malik S; McClune B; Abdallah AO
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):489-496. PubMed ID: 33962898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
    Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
    Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
    Hose D; Schreder M; Hefner J; Bittrich M; Danhof S; Strifler S; Krauth MT; Schoder R; Gisslinger B; Einsele H; Gisslinger H; Knop S
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):205-212. PubMed ID: 32683487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 83.